HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein.

AbstractBACKGROUND:
Myelin oligodendrocyte glycoprotein (MOG) antibodies have been recently described in children with acute disseminating encephalomyelitis (ADEM), but the clinical and neuroradiological characterisation of this subgroup is lacking.
OBJECTIVE:
To compare the clinical and neuroradiological features of paediatric ADEM with and without MOG antibodies.
METHODS:
Clinical course, cerebrospinal fluid (CSF)-, MRI studies, outcome and MOG status of 33 paediatric ADEM prospectively studied were reviewed.
RESULTS:
MOG antibodies (median 1:2560; range 1:160-1:20 480) were detected in 19 children with ADEM. The majority of children showed a decline of serum MOG-IgG titres over time. Children with MOG antibodies did not differ in their age at presentation, sex ratio, the presence of oligoclonal bands, clinical symptoms or initial severity, apart from a higher CSF cell count (p=0.038), compared with children without MOG antibodies. In addition, further relapsing demyelinating episodes associated with MOG antibodies were observed only in children with MOG antibodies. All 19 children with MOG antibodies had a uniform MRI pattern, characterised by large, hazy and bilateral lesions and the absence of atypical MRI features (eg, mainly small lesions, well-defined lesions), which was significantly different compared to that of children without MOG antibodies (p=0.003; and p=0.032, respectively). In addition, children with MOG antibodies had involvement of more anatomical areas (p=0.035) including the myelon characterised by a longitudinally extensive transverse myelitis (p=0.003), more often a complete resolution of lesions (p=0.036) and a better outcome (p=0.038).
CONCLUSIONS:
Patients with ADEM with MOG antibodies in our cohort had a uniform MRI characterised by large, bilateral and widespread lesions with an increased frequency of longitudinal extensive transverse myelitis and a favourable clinical outcome in contrast to children lacking MOG antibodies.
AuthorsM Baumann, K Sahin, C Lechner, E M Hennes, K Schanda, S Mader, M Karenfort, C Selch, M Häusler, A Eisenkölbl, M Salandin, U Gruber-Sedlmayr, A Blaschek, V Kraus, S Leiz, J Finsterwalder, T Gotwald, G Kuchukhidze, T Berger, M Reindl, K Rostásy
JournalJournal of neurology, neurosurgery, and psychiatry (J Neurol Neurosurg Psychiatry) Vol. 86 Issue 3 Pg. 265-72 (Mar 2015) ISSN: 1468-330X [Electronic] England
PMID25121570 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightPublished by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Chemical References
  • Autoantibodies
  • Immunoglobulin G
  • MOG protein, human
  • Myelin-Oligodendrocyte Glycoprotein
Topics
  • Adolescent
  • Autoantibodies (blood)
  • Brain (immunology, pathology)
  • Child
  • Child, Preschool
  • Diagnosis, Differential
  • Encephalomyelitis, Acute Disseminated (diagnosis, immunology)
  • Female
  • Humans
  • Immunoglobulin G (blood)
  • Magnetic Resonance Imaging
  • Male
  • Multiple Sclerosis (diagnosis, immunology)
  • Myelin-Oligodendrocyte Glycoprotein (immunology)
  • Myelitis, Transverse (diagnosis, immunology)
  • Neuromyelitis Optica (diagnosis, immunology)
  • Prognosis
  • Prospective Studies
  • Spinal Cord (immunology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: